Skip to content

Analysis of Factors Influencing the Efficacy of Levamlodipine Benzoate and Its Population Pharmacodynamic Modeling

Analysis of Factors Influencing the Efficacy of Levamlodipine Benzoate and Its Population Pharmacodynamic Modeling

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05958524
Enrollment
150
Registered
2023-07-24
Start date
2022-12-15
Completion date
2023-11-01
Last updated
2023-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Patients, Monotherapy

Keywords

levamlodipine besylate;monotherapy;, Population pharmacodynamics

Brief summary

1. Preliminarily explore the correlation factors of differences in the efficacy of levamlodipine besylate in the treatment of hypertension. 2. Quantitatively analyze the influence of covariates such as patient demographic factors, personal history, combined medications, and biochemical indicators on the efficacy of levamlodipine besylate, and establish a population pharmacokinetic model of levamlodipine besylate, to achieve clinical Individualized treatment and rational drug use.

Detailed description

This study is a retrospective study, which intends to collect and extract relevant information from outpatient medical records from the information center of our hospital, and evaluate the difference in the efficacy of antihypertensive treatment with levamlodipine besylate in newly diagnosed hypertensive patients in our hospital; After antihypertensive treatment with levamlodipine besylate, the correlation analysis was carried out on the influencing factors of blood pressure control in the follow-up, and the covariates such as demographic factors, personal history, combined medications, and biochemical indicators were initially explored. The curative effect of dipine. Through the population pharmacokinetic modeling method of quantitative pharmacology, the influence of covariates such as demographic factors, personal history, combined medication, and biochemical indicators on the curative effect of levamlodipine besylate was quantitatively explored. The population pharmacokinetic model of levamlodipine besylate was established in order to provide reference for clinical individualized treatment and rational drug use.

Interventions

None listed

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Newly diagnosed patients with hypertension in our hospital (sex, age is not limited). 2. Patients whose initial treatment is levamlodipine besylate.

Exclusion criteria

1. Patients who cannot be followed up regularly or are lost to follow-up after initial diagnosis and treatment. 2. Patients who were initially treated with other antihypertensive drugs. 3. Blood pressure was not measured when the patient came to the hospital for follow-up.

Design outcomes

Primary

MeasureTime frameDescription
The systolic blood pressurePatient's follow-up after initial treatment was 1 monthThe systolic blood pressure was measured at rest
The diastolic blood pressurePatient's follow-up after initial treatment was 1 monthThe diastolic blood pressure was measured at rest

Countries

China

Contacts

Primary ContactXian Yu, professor
1clinicaltrial@hospital.cqmu.edu.cn18512356862
Backup ContactGuoxing L
2315714374@qq.com18875213526

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026